Loading clinical trials...
Loading clinical trials...
Multicentre,Randomized,Double-Blind,Double-Dummy,3period,6Seq,Crossover,Active&Placebo,SD PD Study to Evaluate Therapeutic Equivalence of Test Tiotropium Bromide Inh. Powder to Reference SPIRIVA® HANDIHALER in Subjects w/COPD*
Conditions
Interventions
Test Product (tiotropium bromide inhalation powder)
18 mcg of Spiriva (Reference Product)
+1 more
Locations
17
United States
Investigational Site 203
Anderson, South Carolina, United States
Investigational Site 204
Gaffney, South Carolina, United States
Investigational Site 205
Union, South Carolina, United States
Investigational Site 119
Ahmedabad, Gujarat, India
Investigational Site 101
Ahmedabad, Gujarat, India
Investigational Site 120
Gandhinagar, Gujarat, India
Start Date
March 24, 2022
Primary Completion Date
November 29, 2022
Completion Date
November 29, 2022
Last Updated
April 10, 2023
NCT07383896
NCT07509606
NCT07477600
NCT07462221
NCT07351929
NCT06717659
Lead Sponsor
Phargentis SA
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions